A Phase 1 study of KH658 gene therapy in neovascular age-related macular degeneration
Recruiting Phase 1,Phase 2 NCT06458595
Study Description
A study to test the safety and effectiveness of a new gene therapy called KH658 in treating wet age-related macular degeneration
Study Details
- Registry ID:
- NCT06458595
- Conditions:
- Age-related Macular Degeneration
- Phase:
- Phase 1,Phase 2
- Target Enrollment:
- 44 participants
- Start Date:
- Age Range:
- 50–85 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Tianjin Medical University General Hospital
Tianjin, China
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.